NEW YORK (GenomeWeb News) – Molecular Detection and Eldan today announced an exclusive agreement for distribution of MDI's Detect-Ready MRSA panel in Israel and the Palestinian territories.
Financial and other terms of the deal were not disclosed. Eldan, based in Petach Tikva, Israel, is a diagnostic distributor that is part of the Neopharm Group.
The Detect-Ready MRSA panel is CE-marked for detecting methicillin-resistant Staphylococcus aureus and methicillin-sensitive S. aureus. In a joint statement, the two companies said that the panel is the only marketed PCR-based screen proven to be able to discriminate between MRSA, MSSA, and other related bacteria.
The test kits are off-the-shelf, room temperature-stabilized and are compatible with multiple real-time PCR platforms, including the Roche LightCycler, Qiagen Rotor-Gene, and Cepheid SmartCycler.
The panel is currently available in the UK, Germany, Ireland, Switzerland, Spain, Austria, Australia, the Netherlands, Belgium, and Luxembourg. It is in late-stage development in the US.